NKGen Biotech, Inc. Common Stock (NKGN) Revenue History
Annual and quarterly revenue from 2021 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NKGN Revenue Growth
NKGN Revenue Analysis (2021–2024)
As of May 8, 2026, NKGen Biotech, Inc. Common Stock (NKGN) generated trailing twelve-month (TTM) revenue of $652,000. The most recent quarter (Q1 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, NKGN's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $426,000 in 2021.
When compared to Healthcare sector peers including FATE (-51.2% YoY), STTK (-78.3% YoY), and AGEN (+10.4% YoY). Compare NKGN vs FATE →
NKGN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NKGNCurrent | $652,000 | - | - | - | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 STTK | $1M | -78.3% | -36.8% | -5150.8% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
NKGN Historical Revenue Data (2021–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-26,966,000 | - |
| 2023 | $0 | -100.0% | $0 | - | $-29,746,000 | - |
| 2022 | $77K | -81.9% | $59K | 76.6% | $-24,346,000 | -31618.2% |
| 2021 | $426K | - | $396K | 93.0% | $-21,861,000 | -5131.7% |
See NKGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NKGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NKGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNKGN — Frequently Asked Questions
Quick answers to the most common questions about buying NKGN stock.
Is NKGN's revenue growth accelerating or slowing?
NKGN TTM revenue: $652000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is NKGN's long-term revenue growth rate?
NKGen Biotech, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is NKGN's revenue distributed by segment?
NKGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2024 are available for download. Segment mix reveals concentration and diversification trends.